ADHD Trial, Recruiting NCT06221358 Sponsor: University of Calgary Condition: ADHD
Back to Adhd

ADHD Trial, Recruiting

NCT06221358
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 6 to 24 years old.
  • People living in Western Canada (Alberta, British Columbia, Saskatchewan, or Manitoba).
  • People who have been diagnosed with ADHD (any type).
  • People who are starting treatment with a form of Methylphenidate that is not the immediate-release version.

Who may not be able to join:

  • People who have also been diagnosed with a psychotic disorder, bipolar disorder, or an eating disorder.
  • People who are considered to have a significant risk of suicide.
  • People who have an intellectual disability, a diagnosis of autism spectrum disorder (ASD), or a diagnosis of tics or Tourette syndrome.
  • People who have used alcohol or substances at a high-risk level — meaning monthly or more often — within the past 12 months.
  • People who have started talk therapy or brain stimulation therapy within 8 weeks before being referred to the trial, or who plan to start or change these types of therapies during the study.
  • People who have had a liver transplant or a bone marrow (stem cell) transplant at any point in the past, as this can affect the accuracy of certain genetic test results used in the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chad Bousman, MPH, PhD, University of Calgary

Phone: 5875739747

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Calgary
Registry
ClinicalTrials.gov
Start date
1 April 2024
Est. completion
31 August 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in ADHD symptom severity; Side effect frequency and severity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov